As an alternative to the obviously irreversible procedure of stallion castration, Equine medical company Pfizer produced the product Equit' of which they officially say it is "not a vaccine or a chemical castration method". The product is registered for use on mares, but many high performance international riders are welcoming the 'side-effect' of the product to reduce testosterone induced behaviour of their dressage stallions.
What began over 15 years ago with the birth of Dolly the sheep has developed into a global network of research and innovation which has already had a major impact on the world of dressage. "I first heard about embryonic cloning in the 90's and somatic cloning in 1996 with the birth of Dolly," Eric Palmer, founder of the French cloning company Cryozootech, told Eurodressage.
Most popularly known as Equine Cushing's Syndrome, Pituitary Pars Intermedia Dysfunction (PPID) has been noted to be present in approximately 15-30% of the equine population with an increased prevalence (up to 76%) in the older horse population.
American equestrian magazine The Horse published an article about a British study which links suspensory injuries to excessive extended trot. Suspensory ligament injuries are relatively common in dressage horses, but there is little scientific information available on their causes.
Roly Owers, chief executive of World Horse Welfare, urged the public at the charity’s annual conference in London on 15 November 2012 to recognise the valuable contribution horses make to the economy, culture and society, and urgently called for the government to better protect British horses from the spread of disease.